OSE Immunotherapeutics is an immunotherapy company based in Nantes and Paris, France and listed on the Euronext Paris exchange. OSE is developing immunotherapies for the treatment of solid tumours and autoimmune diseases and has established several partnerships with large pharma companies.
OSE Immunotherapeutics is a drug developer that focuses on both oncology and immune disorders, with an R&D pipeline diversified across different indications and mechanisms of action. Long-term collaborations with top research institutions enable the company to identify novel targets in a cost-effective and time-efficient manner and develop products for R&D and out-licensing. The success of this model is demonstrated by several commercial partnerships, including a deal with Boehringer Ingelheim (BI) for a total value of €1.1bn plus royalties. OSE’s most advanced internal programme is cancer vaccine Tedopi for NSCLC (Phase III), with step 1 successfully completed. In December 2019, OSE announced it had successfully completed a Phase I trial with OSE-127 (anti-IL-7), which is partnered with Servier. In May 2020, OSE also announced a COVID-19 prophylactic vaccine programme, which could enter clinical trials as soon as end-2020.
OSE operates within the field of immunotherapy and has products in development for both immunological diseases and cancer indications. We expect OSE’s strong relationships with research institutions and internal expertise to be a significant advantage in continuing to develop pipeline products with partnering potential.